



ASX Announcement and Media Release

(ASX:SIE)

RESULTS OF ANNUAL GENERAL MEETING

Monday 29 June 2009

SciGen Ltd wishes to advise that all resolutions contained in the Notice of Annual General Meeting were duly voted on in accordance with Section 251 AA of the Corporations Act 2001 and ASX Listing Rule 3.13.2

The following information is provided in relation to the resolutions considered by shareholders at the Annual General Meeting held on 29 June 2009 at 9.30am in Singapore.

RESOLUTION	DESCRIPTION	FOR	AGAINST	ABSTAIN	NO INSTRUCTION	RESULT
1	Adoption of the Audited Accounts – 31 December 2008	501,137,403	-	-	-	CARRIED
2	Re-election of Mr. Saul Mashaal	1,075,706	500,061,697	-	-	NOT CARRIED
3	Re-election of Mr. Paul Freiman	1,095,706	500,041,697	-	-	NOT CARRIED
4	Re-election of Mr. Kenneth Gross	501,131,903	5,500	-	-	CARRIED
5	Re-election of Mr. Adam Wilczega	501,131,903	5,500	-	-	CARRIED
6	Re-election of Mr. Adam Polonek	501,131,903	5,500	-	-	CARRIED
7	Re-election of Mr. Marcin Dukaczewski	501,131,903	5,500	-	-	CARRIED
8	Re-election of Mr. Janusz Guy	501,131,903	5,500	-	-	CARRIED
9	Re-appointment of Auditors - KPMG	501,137,403	-	-	-	CARRIED
10	Approval of Directors Remuneration - 31 December 2008	500,793,711	342,126	-	-	CARRIED
11	Authority to Allot & Issue Shares pursuant to Section 161 of the Companies (Amendment) Act 2004 of the Republic of Singapore	500,418,008	719,395	-	-	CARRIED
12	Issue & Allotment of Options to Mr. Paul Freiman	197,000	500,938,837	-	-	NOT CARRIED
13	Issue & Allotment of Options to Mr. Kenneth Gross	17,000	501,118,837	-	-	NOT CARRIED

RESOLUTION	DESCRIPTION	FOR	AGAINST	ABSTAIN	NO INSTRUCTION	RESULT
14	Issue & Allotment of Options to Dr. Marian Gorecki	17,000	501,118,837	-	-	NOT CARRIED
15	Issue & Allotment of Options to Mr. Adam Wilczega	17,000	501,118,837	-	-	NOT CARRIED
16	Issue & Allotment of Options to Mr. Adam Polonek	17,000	501,118,837	-	-	NOT CARRIED
17	Issue & Allotment of Options to Mr. Waldemar Krzewski	17,000	501,118,837	-	-	NOT CARRIED
18	Issue & Allotment of Options to Dr. Joanna Szymanska-Bulska	17,000	501,118,837	-	-	NOT CARRIED
19	Issue & Allotment of Options to Mr. Marcin Dukaczewski	17,000	501,118,837	-	-	NOT CARRIED
20	Issue & Allotment of Options to Mr. Janusz Guy	17,000	501,118,837	-	-	NOT CARRIED
21	Issue & Allotment of Options to Mr. Adam Allerhand	17,000	501,118,837	-	-	NOT CARRIED
22	Issue & Allotment of Options to Mr. David Mashaal	26,690	501,110,713	-	-	NOT CARRIED
23	Approval of Employee Share Option Plan	816,506	500,319,331	-	-	NOT CARRIED
24	Approval of Termination Benefits	500,068,561	1,067,276	-	-	CARRIED

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes a third generation Hepatitis B Vaccine and therapeutics such as rhuman Growth Hormone, rhuman Insulin, GCSF and Interferon Alpha 2b.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, S.Korea, Vietnam, China, India, Israel and Philippines, distribution channels in Taiwan, China, India, Pakistan, Thailand and Indonesia, manufacturing facilities in Israel, India and China and a contract manufacturer in Poland, Bioton S.A.

For further information: Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: gdunlop@scigen.com.au	Adam Allerhand Chairman & CEO SciGen Ltd +65 6779 6638